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Summary A role for antigen stimulation in lymphoid neoplasia has been postulated and is supported by
indirect evidence that suggests that the interaction of antigen with both T cells and B cells may constitute an
epigenetic event that can contribute to tumour induction or tumour progression. Using myc-bearing transgenic
mice that develop mainly clonal T-cell lymphomas we have investigated the possibility that endogenous
antigen-mediated clonal deletion might be overridden in tumorigenesis. CD2-myc transgenic mice were
backcrossed on to a CBA/Ca background to ensure Mtv-mediated deletion of VPI 1-expressing T cells in the
resultant offspring. Lymphomas arising from these mice were subsequently screened for VPl expression.
There was a clear correlation between the age at which mice developed neoplasia and the tumour phenotype.
Mice with CD4- CD8+ tumours succumbed to thymic lymphoma at a significantly younger age than mice
developing CD4+ CD8+ tumours. A small number of tumours consisted of the 'forbidden' VP I I phenotype,
showing that cells vulnerable to transformation could escape negative selection. The majority of the VBI 1-
positive tumours were CD4- CD8+ and were only observed in mice showing clinical evidence of tumour
development at a relatively young age. The phenotype of these cells and the age at which tumours arose
suggests that T cells escaping tolerance may be susceptible to transformation.
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There is now considerable evidence to suggest that the
oncogenic transformation of healthy tissue involves a series
of events, ultimately resulting in the appearance of the fully
malignant phenotype. To study this process in the T-cell
lineage we have produced two lines (800 and 900 series) of
transgenic mice that harbour the human c-myc gene linked to
the CD2 dominant control region. These CD2-myc transgenic
mice display a moderate incidence of T-cell lymphoma
development but it is obvious from the stochastic appearance
and the clonal nature of these tumours that one or more
secondary events are necessary for transformation to the fully
neoplastic phenotype (Stewart et al., 1993). These mice are,
therefore, a useful model with which to explore those
oncogenic events that can cooperate with myc in T-cell
leukaemogenesis. In this study, we investigated the possibility
that antigenic stimulation of T cells through the T-cell recep-
tor (TCR) might, under certain circumstances, complement
the action of oncogenes such as myc in T-cell transformation.
The potential role of antigen stimulation in the transfor-
mation or clonal expansion of lymphoid tissue is not known
but there is indirect evidence to implicate antigenic activation
of lymphocytes in tumorigenesis. Follicular lymphomas are
often committed to the production of autoantibodies and it
has been suggested that B cells responsive to the continuous
presence of self antigen are susceptible to transformation
(Dighiero et al., 1991). Further, Bahler and Levy (1992) have
reported that there is evidence for antigen selection in the
development of follicular lymphomas. Analysis of a thymic
lymphoma associated with a field case of feline leukaemia
virus (FeLV) infection revealed the presence of a provirus
which had incorporated a fully processed TCR gene, raising
the possibility that antigen stimulation or inappropriate
antigen recognition may have been important in the genesis
of this tumour (Fulton et al., 1987). Studies involving murine
radiation leukaemia virus (RadLV) have shown that free
virus particles can modulate the growth of a RadLV-induced
T-cell lymphoma cell line (O'Neill, 1994) and that the VP
repertoire of RadLV-induced lymphomas is restricted,
indicating non-random selection (Sen-Majumdar et al., 1994).
The inbred mouse is a useful model with which to study
endogenous antigen stimulation. Proviral mammary tumour
virus (Mtv) sequences resident in the mouse genome comprise
a polymorphic family of superantigens that react with
different T-cell families defined by their VP gene usage and
have, therefore, an important role in shaping the T-cell reper-
toire. Expression of the sag gene located in the 3' long
terminal repeat (LTR) of endogenous mammary tumour pro-
viral sequences results in the stimulation of mature T cells
and in the clonal deletion of developing T cells bearing
specific VP gene products (for reviews see Acha-Orbea &
Palmer, 1991; Simpson,- 1992; Marrack et al., 1993; Simpson
et al., 1993).
We have exploited the presence of these endogenous
superantigens to investigate the relationship between TCR VP
restriction and lymphomagenesis using the tumour-prone
CD2-myc transgenic mice. The appearance of tumours exp-
ressing a 'forbidden' VP phenotype would indicate that
tumorigenesis bypasses or overrides negative selection. Here
we present data to demonstrate that a small proportion of
CD4- CD8+ T-cell tumours can express a 'forbidden' Vpll
phenotype.
Materials and methods
Experimental animals
The CD2-myc transgenic mice have been described previously
(Stewart et al., 1993). The genetic background of these mice
was a mixture of C57B16/J and CBA/Ca inbred lines. The
transgenic mice were backcrossed to CBA/Ca mice and
tumours arising in the offspring were analysed. This was
carried out to ensure that the offspring all carried a func-
tional I-Eo gene necessary for the deletion of autoreactive V,B
T-cell families. Mice developing lymphomas were culled as
soon as clinical signs of malaise were apparent.
Hybridisation ofDNA and RNA
Preparation of high-molecular weight DNA from mouse tis-
sues was carried out using standard protocols (Hogan et al.,
1986). DNA was digested with the appropriate restriction
endonucleases, separated by agarose gel electrophoresis,
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transferred to nylon filters and hybridised to the appropriate
radiolabelled probes at high stringency using the protocols
described by Sambrook et al. (1989). Random priming (Ran-
dom Priming Kit, Amersham) and radiolabelling of these
probes was also carried out using methods described by
Sambrook et al. (1989). Transgene sequences were identified
using a human c-myc exon 3 probe (1.38 kb, CJaI-EcoRI).
Cellular RNA was extracted from mouse tissues using the
RNAzol B method (Biogenesis). Samples of 20 yig were
separated by electrophoresis on 1% agarose gels containing
2.2 M formaldehyde, transferred on to nylon filters and hyb-
ridised using procedures described by Sambrook et al. (1989).
VP11 expression was determined using a probe derived from
a 0.4 Kb EcoRI/Sst fragment of the VPI1 variable region
(kindly supplied by Julian Dyson, MRC Clinical Research
Centre, Harrow, UK).
Flow cytometry
Thymus tissue was mixed with phosphate-buffered saline and
minced using sterile scissors and the dead cells removed by
centrifugation through a Ficoll-hypaque gradient (2000g for
10 min). Cells were directly labelled by resuspending them at
2.5 x 106 ml with a 1:40 dilution of pretitrated antibody.
Reaction mixtures (400ptl) were incubated at 4°C for 35 min
before washing and analysis. Rat monoclonals FITC anti-
CD8 (clone 53-6.7), RD anti-CD4 (clone YTS 191-1.2) and
biotin anti-CD3 (clone YCD3-1) were obtained from Gibco.
Rat anti-VP1 II antibody (clone RR3-15) was obtained from
Pharmingen.
Results
Small numbers ofCD2-myc/CBA tumours expressed a
forbidden VP3JJ phenotype
CD2-myc transgenic mice harbour the human c-myc gene
linked to the CD2 dominant control region and as a result
these mice display a moderate incidence of spontaneous T-
cell lymphoma. We sought to use these mice to investigate
the influence of T-cell negative selection on tumour develop-
ment. The presence of endogenous superantigens in mice
results in the clonal deletion of specific VP expressing
families. We wished to establish the CD2-myc mice
(originally derived from C57B1/6 and CBA/Ca inbred
strains) on a background that should result in the deletion of
VPJl1 cells. CBA/Ca mice carry Mtv loci 8 and 9 together
with a functional I-E gene (Simpson, 1992), by backcrossing
onto CBA/Ca mice it was predicted that the offspring would
delete Vp11-expressing cells. To confirm that these F, mice
could present endogenous superantigen a representative sam-
ple of the tumours was screened for the presence of an intact
I-Ea gene (J Picard, personal communcation). All CBA/CD2-
myc backcrossed mice examined were found to have at least
one allele with an intact I-E a-chain gene. The potential role
of autoreactive cells in lymphoma development was inves-
tigated by screening tumours for VP111 expression.
The phenotype of tumours arising from CBA backcrossed
transgenic mice was investigated using flow cytometry. All
tumours analysed were CD3+ and the majority of tumours
could be divided into two T-cell phenotypes. Nearly 70% of
tumours were composed of cells that were predominantly
CD4+ CD8+ and 20% were predominantly composed ofcells
of the CD4- CD8+ phenotype (Table I). These results are
similar to those previously observed in the parental CD2-myc
mice (Stewart et al., 1993). Backcrossing the mice did, how-
ever, result in an increased incidence of tumour development
in both lines. In the 800 line and 900 lines the incidence rose
from 19% (22/114) to 30% (102/340) and from 3% (2/66) to
34% (25/73) respectively.
Flow cytometry analysis of VP11 usage in tumour samples
of CD2-myc/CBA mice showed that 3 of the 17 CD4- CD8+
tumours analysed were largely composed of this 'forbidden'
cell type and a fourth CD4- CD8+ tumour contained a
major subpopulation of VP111-positive cells. In contast VP11
cells were only found in 2 of the 61 CD4+ CD8+ tumours.
To confirm that VPII expression was present in these sam-
ples we analysed two of these tumours (8V9 and 9V10) for
V13ll mRNA by Northern blot hybridisation using a V31ll-
specific probe, these results confirmed that both tumours
expressed the VP B11 transcript. The flow cytometry results and
Northern blot results of these two tumours are shown in
Figures 1 and 2 respectively. Therefore it appears that
tumours representing T-cell families that would normally be
deleted can be present in transgenic mice prone to thymic
lymphoma development but their appearance is biased to the
CD8 single positive subset.
Tumour phenotype in CD2-myc mice was highly correlated
with age
Transgenic CBA backcrossed mice developed spontaneous
thymic lymphomas from 2 months of age. The majority of
mice that developed tumours did so between 3 and 9 months
of age, with only a small proportion of mice greater than 9
months of age succumbing to lymphoma development. The
CD4/CD8 phenotype of the T-cell tumours was closely cor-
related with the age at which mice develop thymic lym-
phoma. Mice developing thymic lymphoma at a com-
paratively young age were much more likely to be CD4-
CD8+ than mice developing lymphoma at an older age. The
average age at which mice developed CD4- CD8+ tumours
was 115 days whereas the average age of mice developing
CD4+ CD8+ tumours was 174 days. The difference between
the two groups is highly significant (Mann-Whitney test,
P<0.001) and suggests that there is an age-related suscep-
tibility to the development of CD4- CD8+ tumours. The
over-representation of CD4- CD8+ tumours in young mice
is shown in Figure 3.
The appearance of CD4- CD8+ Vpll tumours was also
correlated with age. The mice that developed VP1 1-expressing
tumours of the CD4- CD8+ phenotype were amongst the
youngest mice to succumb to tumour development. Overall
the average age at which mice develop thymic lymphoma is
161 days with a wide range from 65 to 333 days. The mice
developing CD4- CD8+ V13l l-positive tumours all died
between 65 and 94 days of age. The two mice that developed
CD4+ CD8+ VP111-positive tumours died at 109 and 126
days.
In all of the tumours examined the thymus was greatly
enlarged but gross pathological changes in the spleen and
lymph nodes were much more variable. As a result the
tumours could be broadly divided into two types: those that
had only slight or no obvious splenic involvement and those
that had gross involvement of the secondary lymphoid
organs. There was a correlation between the phenotype of
the tumours and the observed gross pathology. In those
tumours in which gross involvement of secondary lymphoid
organs was not obvious, 90% of tumours were CD4+ CD8+
and only 10% of tumours were CD4- CD8+ whereas there
was a far higher representation of CD4- CD8+ tumours
showing gross involvement of the secondary lymphoid
organs. These results are shown in Table II.
Table I The phenotype of lymphoid tumours from the CD2-myc transgenic mice (800 and 900 lines) based on flow
cytometry analysis of CD4 and CD8 expression.
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Figure 1 Flow cytometry analysis of Vp1, CD3, CD4 and CD8 surface expression of thymic lymphoma cells from Vp1l-positive mice (a) 8V9 and (b) 9V10. (c) Thymic lymphoma cells from a VPI1 1-negative mouse (8V21). (d) Thymocytes from a CBA control
mouse.
Discussion
The multistep model of tumour induction is well established
and it has been suggested that as many as 3-6 'hits' may be
involved in leukaemogenesis (Berns, 1993). In this study we
have investigated the possibility that antigen stimulation
could constitute an epigenetic event with a contributory role
in tumorigenesis. In the CD2-myc mouse model the myc
transgene predisposes to tumour development, although these
tumours arise some time after birth and are clonal or oligoc-
lonal in origin. It is conceivable that developmentally
acquired epigenetic factors such as the acquisition of self-
reactivity during T-cell receptor rearrangement could accel-
erate tumorigenesis. In this context it is of interest that the
tumours bearing potentially autoreactive cells were amongst
the earliest to develop and that in general CD8 single positive
tumours were more common in mice succumbing to T-cell
lymphoma at an early age.
Three out of 17 CD4- CD8+ tumours displayed a 'forbid-
den' VPil phenotype and a fourth tumour from this series
had a large VPII subpopulation. Two alternative hypothesis
are consistent with the appearance of these tumours and our
understanding of T-cell ontogeny. First, the development of
such tumours may be indicative of abortive negative selec-
tion. The interaction of the T-cell receptor (TCR) with self-
antigen normally results in the induction of apoptosis. If,
however, the cells had sustained oncogenic changes before
negative selection they might fail to undergo programmed
cell death, particularly if some of these lesions inhibited
apoptosis. Such an event would result in the survival of
transformed cells carrying a potentially autoreactive VP gene
product.
An alternative possibility is that tumours arise from that
small population of autoreactive cells that appear to escape
clonal deletion in the course of normal development. It is
well established that clonal deletion of T-cells expressing
potentially autoreactive VP genes is incomplete in neonatal
mice (Smith et al., 1989; Schneider et al., 1989; Jones et al.,
1990). Although a number of studies have indicated that
autoreactive T-cells escaping thymic deletion are rendered
anergic to a variety of stimuli (Ramsdell et al., 1989; Ram-
mensee et al., 1989; Blackman et al., 1990; Smith et al.,
1989). (Jones et al., 1990) have shown that a small popula-
tion of mature (mainly CD4- CD8+) V,B-reactive cells are
present in the thymus of neonatal mice and that these cells
are functional as defined by their capacity to proliferate and
generate interleukin 2 (IL-2). The transient presence of such
cells suggests that thymocytes escaping clonal deletion are
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Table II The relationship between gross pathology and tumour phenotype in CBA/CD2-myc mice
CD4+ CD8+a CD4- CD8+a CD4+ CD8+b CD4- CD8+b
Doublepositive Singlepositive Doublepositive Singlepositive
CBA/CD2-myc 800 and 900 lines 21 2 8 7
a Primarily thymic lymphomas without obvious involvement of secondary lymphoid organs. b Thymic
lymphomas with extensive involvement of secondary organs.
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Figure 2 Northern blot analysis of VP111 mRNA expression in
control or tumour thymocytes. Arrow denotes Vpl1 transcript.
immediately rendered anergic and that for a period of time
there exists a population of cells that are reactive to self-
antigens. There are interesting parallels between these
findings and the observations regarding tumorigenesis in the
CD2-myc mice. Mice which develop tumours at a young age
tend to develop CD4- CD8+ tumours, some of which exp-
ress a 'forbidden' VP phenotype. It is possible, therefore, that
these tumours (or at least a proportion of them) arise from
this relatively transient population of mature CD4- CD8+ T
cells that escape clonal deletion. The tumours might either
arise from cells that have not yet been rendered anergic or
from cells in which anergy has been reversed; Andreau-
Sanchez et al. (1991) have shown that the anergic state of
self-reactive T cells can be reversed.
Whether the tumours arise from cells before selection or
from a transient population of normal cells that have escaped
clonal deletion, the continued presence of endogenous
superantigen makes stimulation of these cells a possibility as
it is clear that single positive mature CD8 cells can be
stimulated by endogenous superantigen in combination with
class II MHC (Webb and Sprent, 1990).
An in vitro study has previously shown an oncogenic rela-
tionship between c-myc and antigen stimulation in a hybrid
cell line (Kubota et al., 1992). A lymphoma line in which
c-myc is deregulated loses its transformed phenotype and
down-regulates c-myc when fused to an Mls-1a antigen-
ig f4 imontha)
Figure 3 The relationship between tumour phenotype (based on
surface expression of CD4 and CD8) and the age at which mice
develop lymphomas. _, CD4- CD8+; M1, CD4+
CD8+.
specific non-tumorigenic cell line. However, repeated antigen
stimulation can result in autonomous growth and can reverse
the down-regulation of c-myc. In vivo studies involving
retrovirus-induced lymphomagenesis have also suggested a
role for antigen stimulation in tumour initiation and/or pro-
gression. De Heer et al. (1992) reported that 2 out of 14
retrovirus induced lymphomas arising in AKR mice exp-
ressed a 'forbidden' VP phenotype. A restricted VP phenotype
has also been observed in T-cell lymphomas induced with
RadLV, although the appearance of a 'forbidden' phenotype
was not reported (Sen-Majumdar et al., 1994). However,
there is an important difference between these studies and the
results reported here. The mechanism of viral-induced lym-
phomagenesis is complex and it has been suggested that
RadLV may exert its oncogenic action at more than one
stage in the transformation process (O'Neill, 1994).
Overall these findings show that cells vulnerable to trans-
formation can, under certain circumstances, escape the
mechanisms that maintain tolerance. It is possible that dou-
ble positive cells expressing a forbidden VP phenotype repre-
sent cells that have been transformed before selection. How-
ever, the identification of apparently mature T-cell tumours
bearing this phenotype was more surprising (particularly as
this was not an infrequent finding) and raises the possibility
that antigen stimulation may play a role in tumour induction
or in the clonal expansion of tumours. In this study we have
only sampled a small part of the autoreactive repertoire but
these findings may represent a more generic phenomenon.
We intend to address this issue both by examining the
tumour phenotype from mice that delete a wider range ofVP
families and by using exogenous superantigen.
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